Modality
Vaccine
MOA
BTKi
Target
WRN
Pathway
Autophagy
SMACFPTSD
Development Pipeline
Preclinical
~Mar 2017
→ ~Jun 2018
Phase 1
~Sep 2018
→ ~Dec 2019
Phase 2
~Mar 2020
→ ~Jun 2021
Phase 3
Sep 2021
→ Oct 2031
Phase 3Current
NCT08091234
1,436 pts·CF
2021-09→2025-05·Completed
NCT03851721
650 pts·PTSD
2023-01→2031-10·Not yet recruiting
2,086 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-05-2110mo agoPh3 Readout· CF
2031-10-125.5y awayPh3 Readout· PTSD
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Complet…
P3
Not yet…
Catalysts
Ph3 Readout
2025-05-21 · 10mo ago
CF
Ph3 Readout
2031-10-12 · 5.5y away
PTSD
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08091234 | Phase 3 | CF | Completed | 1436 | NT-proBNP |
| NCT03851721 | Phase 3 | PTSD | Not yet recr... | 650 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Ivosotorasib | Vertex Pharma | Preclinical | CD38 |